[go: up one dir, main page]

MX2019002115A - Terapias de combinacion para el tratamiento de carcinoma hepatocelular. - Google Patents

Terapias de combinacion para el tratamiento de carcinoma hepatocelular.

Info

Publication number
MX2019002115A
MX2019002115A MX2019002115A MX2019002115A MX2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A MX 2019002115 A MX2019002115 A MX 2019002115A
Authority
MX
Mexico
Prior art keywords
hepatocellular carcinoma
treatment
combination therapies
inhibitor
combination
Prior art date
Application number
MX2019002115A
Other languages
English (en)
Inventor
Selvaraj Anand
Smith Peter
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019002115A publication Critical patent/MX2019002115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona en la presente una terapia de combinación útil para el tratamiento de carcinoma hepatocelular y/o colangiocarcinoma intrahepático. La combinación comprende un inhibidor de FGFR4 y un inhibidor de CDK 4/6.
MX2019002115A 2016-08-23 2017-08-23 Terapias de combinacion para el tratamiento de carcinoma hepatocelular. MX2019002115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378455P 2016-08-23 2016-08-23
PCT/US2017/048183 WO2018039324A1 (en) 2016-08-23 2017-08-23 Combination therapies for the treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX2019002115A true MX2019002115A (es) 2019-07-08

Family

ID=59772765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002115A MX2019002115A (es) 2016-08-23 2017-08-23 Terapias de combinacion para el tratamiento de carcinoma hepatocelular.

Country Status (14)

Country Link
US (1) US20190175598A1 (es)
EP (1) EP3503923B1 (es)
JP (1) JP7190425B2 (es)
KR (1) KR102466192B1 (es)
CN (1) CN109803684B (es)
AU (1) AU2017315357B2 (es)
BR (1) BR112019003722A2 (es)
CA (1) CA3034875C (es)
ES (1) ES2966469T3 (es)
IL (1) IL264950B2 (es)
MX (1) MX2019002115A (es)
RU (1) RU2769251C2 (es)
SG (1) SG11201901472TA (es)
WO (1) WO2018039324A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020013915A2 (pt) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
AU2019269159A1 (en) 2018-05-14 2020-11-19 Pfizer Inc. Oral solution formulation
TW202128173A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
WO2021230886A1 (en) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
WO2023232012A1 (zh) 2022-05-30 2023-12-07 石药集团中奇制药技术（石家庄）有限公司 用于治疗癌症的药物组合和药物组合物
WO2025113607A1 (zh) * 2023-11-30 2025-06-05 石药集团中奇制药技术（石家庄）有限公司 联合治疗肿瘤的药物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
PT1259507E (pt) 2000-01-18 2004-12-31 Aventis Pharma Inc Forma pseudopolimorfica de (-)-cis-2-(2-clorofenil)-5,7-di-hidroxi-8[4r(3s-hidroxi-1-metil)piperidinil]-4h-benzopiran-4-ona
ATE284400T1 (de) 2000-01-18 2004-12-15 Aventis Pharma Inc Ethanolsolvat von (-)-cis-2-(2-chlorphenyl)-5,7- dihydroxy-8- (4r-(3s-hydroxy-1- methyl)piperidinyl)-4h-1-benzopyran-4-on
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2007131101A (ru) 2005-01-21 2009-02-27 Астекс Терапьютикс Лимитед (Gb) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
WO2008007122A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
JP2009543768A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド 医薬組み合わせ
JP2009544602A (ja) 2006-07-21 2009-12-17 アステックス・セラピューティクス・リミテッド サイクリン依存性キナーゼ阻害剤の医学的使用
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
GEP20125502B (en) * 2008-05-23 2012-04-25 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
PT2331547E (pt) 2008-08-22 2014-10-29 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
EP2955183A1 (en) 2010-10-25 2015-12-16 G1 Therapeutics, Inc. Cdk inhibitors
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ES2610931T3 (es) * 2011-07-01 2017-05-04 Novartis Ag Terapia de combinación
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP2934515B1 (en) 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
KR102318306B1 (ko) * 2013-08-14 2021-10-28 노파르티스 아게 암의 치료를 위한 조합 요법
RU2715708C2 (ru) * 2013-10-18 2020-03-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Ингибиторы fgfr4
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
SG10201810057UA (en) 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof

Also Published As

Publication number Publication date
SG11201901472TA (en) 2019-03-28
EP3503923B1 (en) 2023-10-04
ES2966469T3 (es) 2024-04-22
CA3034875A1 (en) 2018-03-01
IL264950A (en) 2019-05-30
AU2017315357B2 (en) 2022-12-01
WO2018039324A1 (en) 2018-03-01
JP2019528302A (ja) 2019-10-10
KR102466192B1 (ko) 2022-11-14
US20190175598A1 (en) 2019-06-13
AU2017315357A1 (en) 2019-02-28
JP7190425B2 (ja) 2022-12-15
CN109803684A (zh) 2019-05-24
KR20190040996A (ko) 2019-04-19
BR112019003722A2 (pt) 2019-05-28
CN109803684B (zh) 2022-08-23
IL264950B1 (en) 2023-09-01
CA3034875C (en) 2024-05-28
RU2019108259A3 (es) 2020-11-24
EP3503923A1 (en) 2019-07-03
IL264950B2 (en) 2024-01-01
RU2769251C2 (ru) 2022-03-29
RU2019108259A (ru) 2020-09-25

Similar Documents

Publication Publication Date Title
MX2019002115A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MY205639A (en) Fgfr/pd-1 combination therapy for the treatment of cancer
EP3662903A3 (en) Combination therapies
GEAP202014670A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2018003472A (es) Moduladores de la expresion de kras.
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
PH12019502174A1 (en) Modulators of pcsk9 expression
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
IL283948A (en) Methods for treating depression
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2019010981A (es) Terapias de combinacion para el tratamiento de cancer de mama.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
WO2016046414A3 (en) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
MX2020011912A (es) Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).